Radiation for HER2 Positive Breast Cancer: 72 Real Stories

72 stories match breast cancer, HER2 positive and radiation. 69 of them mention surgery.

Cancer Stories

Dorian, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Dorian's Survivor Story

Patient Info: Dorian de Salvo, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of March 2024, Dorian had a complete response to TCHP chemotherapy, clear surgical margins, and no lymph-node involvement after surgery, with radiation completed and additional care still expected for several months.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Male Invasive Lobular Breast Cancer With a Pathogenic PALB2 Variant

Patient Info: Anonymized, male, 40s

Biomarkers: ER-positive; PR-positive; HER2 not amplified; pathogenic PALB2 variant

He was disease-free at 1-year follow-up after mastectomy, chemotherapy, and radiotherapy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Metastatic HER2-Positive Breast Cancer With Treatment-Related Telangiectasias

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: HER2-positive; initially ER-negative and PR-negative; metastatic disease weakly ER-positive and PR-negative; germline testing negative

Metastatic Site: left supraclavicular, mediastinal, axillary and…

Living with HER2-positive breast cancer for 9+ years since her 2014 diagnosis, including metastatic disease since 2017. She remained on reduced-dose tucatinib in 2023 while treatment-related telangiectasias improved after dose reduction and electrocautery.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage I Breast CancerBreast Cancer

Five Years Without Breast Cancer Recurrence Despite a Markedly Elevated CA 15-3

Patient Info: Anonymized, female, 70+ | Stage I

Biomarkers: ER-positive, PR-positive, HER2-positive

Five years after her Stage I breast-cancer diagnosis, breast imaging and systemic evaluation showed no evidence of recurrence. The markedly elevated CA 15-3 was traced to a separate renal tumor and normalized after nephrectomy.

PubMed Central
OutcomeCancer-Free / NED
Olivia, who was diagnosed with Stage IV Inflammatory Breast CancerBreast Cancer

Stage IV HER2-Positive Inflammatory Breast Cancer: Olivia's Survivor Story

Patient Info: Olivia Franz, Female, Under 40 | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Bones; distant lymph nodes

As of October 2023, Olivia continued to show no evidence of disease on scans while receiving maintenance trastuzumab and pertuzumab every 3 weeks and zoledronic acid every 3 months for bone health.

MD Anderson
OutcomeCancer-Free / NED
Nikki, who was diagnosed with Stage III Inflammatory Breast CancerBreast Cancer

Stage III HER2-Positive Inflammatory Breast Cancer: Nikki's Patient Story

Patient Info: Nikki, Female | Stage III

Biomarkers: HER2-positive; hormone receptor-positive

After 7 chemotherapy rounds, imaging showed no visible disease, but the team expected possible microscopic cancer. A single mastectomy, radiation and long-term hormone therapy were still planned, so she was not classified as cancer-free.

The Patient Story
OutcomeCare Ongoing / Surgery Planned
Abigail, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HR-Positive Breast Cancer: Abigail's Patient Story

Patient Info: Abigail Myers, female, Under 40 | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-positive

Metastatic Site: bones, brain

Abigail continued living with Stage IV metastatic breast cancer after about 8 years of multiple treatment lines, including therapy for bone and brain metastases.

Dana-Farber
OutcomeLiving With Cancer
Feyama, who was diagnosed with Breast CancerBreast Cancer

HER2-Positive Breast Cancer: Feyama's Survivor Story

Patient Info: Feyama Ashby, Female

Biomarkers: HER2-positive

As of September 2022, Feyama had completed chemotherapy, lumpectomy with lymph-node removal, reconstruction, and 6 weeks of VMAT radiation, and was entering close monitoring for 5 years before survivorship clinic follow-up.

MD Anderson
OutcomeSurvivorship / Surveillance
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Cancer in Accessory Breast Tissue Under Both Arms in a Man

Patient Info: Anonymized, Male

Biomarkers: Left tumor: HER2-positive by gene amplification; ER-negative; PR-negative; Ki-67 70%; p53 staining 80%

After surgery removed both accessory-breast cancers, he continued with adjuvant paclitaxel, trastuzumab and radiation.

PubMed Central
OutcomeCare Ongoing
María, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HER2-Positive Breast Cancer: María's Survivor Story

Patient Info: María Ángeles, Female | Stage II

Biomarkers: HER2-positive

As of March 2022, María Ángeles was 4 years from diagnosis after completing 14 chemotherapy sessions, mastectomy with immediate reconstruction, 21 radiation sessions, and trastuzumab for Stage II HER2-positive breast cancer.

MatchTrial Historias Reales
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

A durable response to trastuzumab in heavily pretreated metastatic breast cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial tumor ER-positive and PR-positive. Metastatic liver biopsy ER-negative and PR-negative with HER2 IHC 1+ and nonamplified. Later biopsy ER and PR weakly positive at 5%–10%, HER2 IHC 1+ and nonamplified, and ERBB3 p. with evidence of HER2/HER3 pathway activation.

Metastatic Site: lungs; hilar and mediastinal lymph nodes; liver; bone

She had ongoing benefit for more than 10 months on trastuzumab and capecitabine, with improved symptoms, lower tumor markers, and a confirmed partial response.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

HER2-positive breast cancer diagnosed during pregnancy and later spread to bone and brain

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Initial tumour: ER 0%, PR <1%, HER2 3+

Metastatic Site: bone (L3)|brain

After treatment and surveillance without new lesions, she developed a large symptomatic occipital brain metastasis 14 months after completing paclitaxel and radiation and died after rapid neurological deterioration.

PubMed Central
OutcomeIn Memory
Christine, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Christine's Survivor Story

Patient Info: Christine Hodgdon, Female, Under 40 | Stage IV

Biomarkers: HER2-positive

Christine had no evidence of disease after 1 year and continued HER2-targeted treatment with regular surveillance scans.

AACR
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Breast Cancer Recurrence in the Parotid Gland Eight Years Later

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Primary breast tumor: ER-positive and HER2-positive. Parotid metastasis: ER-positive, PR-negative, and HER2-positive.

Metastatic Site: left parotid gland

The isolated parotid metastasis was completely resected, one-month PET-CT showed no significant abnormality, and endocrine therapy continued with exemestane.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Nocardia Infection Mimicked Breast Cancer Lung Metastases

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-positive.

The lung nodules resolved with antibiotics and proved infectious rather than metastatic; she remained in good health at the last follow-up in January 2019.

PubMed Central
OutcomeCancer-Free / NED
Ashley, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III BRCA2 Breast Cancer: Ashley's Survivor Story

Patient Info: Ashley, female, Under 40 | Stage III

Biomarkers: BRCA2 positive; HER2 positive

Ashley described herself as cancer-free after chemotherapy, double mastectomy and 30 rounds of radiation, with 10 months of Herceptin planned.

MD Anderson
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Breast CancerBreast Cancer

Triple receptor-positive neuroendocrine breast cancer in a 32-year-old woman

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: ER positive; PR positive; HER2 positive; neuron-specific enolase positive; synaptophysin positive

She was stable on follow-up and was receiving adjuvant chest-wall radiation plus systemic chemotherapy and trastuzumab-based therapy.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage IV Breast Cancer With Long-Term Tumor Regression After Radiation Therapy

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: HER2 positive

Metastatic Site: 8th thoracic vertebra

Follow-up showed near-complete regression of the breast tumor, resolution of the bone lesion, normal tumor markers, and a 2015 biopsy with no tumor cells. Follow-up showed no further recurrence, and she returned to work with good quality of life.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Bilateral Breast Cancers Followed by Metastatic Disease and Long Eribulin Treatment

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: Left primary: ER 90%, HER2 FISH not amplified, Ki67 25%. Right primary: ER 90%

Metastatic Site: lung, pleura, liver, bone

After pelvic bone metastases appeared in 2017, she stopped eribulin, received pelvic radiation and remained on fulvestrant treatment.

PubMed Central
OutcomeCare Ongoing
Sarah, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Sarah's Patient Story

Patient Info: Sarah, Female, Under 40 | Stage IV

Biomarkers: HER2-positive; BRCA and other known hereditary breast cancer genes not identified in family history discussion

As of January 2017, Sarah had been living for almost 3 years with recurrent Stage IV HER2-positive breast cancer and was receiving Kadcyla every 3 weeks.

YouTube — Oncology Associates
OutcomeLiving With Cancer